SEC Filing Summary for Anika Therapeutics, Inc. (ANIK)

This filing details transactions by Stephen D. Griffin, President and CEO of Anika Therapeutics, Inc. On June 3, 2026, Mr. Griffin acquired 12,840 shares of Common Stock through the vesting of Restricted Stock Units (RSUs), with a reported transaction price of $0.0. Following this, his post-transaction shares increased to 49,742. Concurrently, 3,769 shares were retained by the Issuer to cover tax withholding obligations related to the RSUs, with a transaction price of $14.41 per share. This resulted in a post-transaction share count of 45,973. The RSUs granted on June 3, 2024, vest in three equal annual installments starting June 3, 2025, with this transaction representing the second vesting installment.